Liquid chromatography/mass spectrometry analysis of exhaled leukotriene B(4 )in asthmatic children by Montuschi, Paolo et al.
BioMed  Central
Page 1 of 8
(page number not for citation purposes)
Respiratory Research
Open Access Research
Liquid chromatography/mass spectrometry analysis of exhaled 
leukotriene B4 in asthmatic children
Paolo Montuschi*1, Simona Martello2, Marialinda Felli2, Chiara Mondino3, 
Peter J Barnes4 and Marcello Chiarotti2
Address: 1Department of Pharmacology, Faculty of Medicine, Catholic University of the Sacred Heart, Rome, Italy, 2Department of Forensic 
Medicine, Faculty of Medicine, Catholic University of the Sacred Heart, Rome, Italy, 3Department of Immunodermatology, Istituto Dermopatico 
dell'Immacolata, IDI, IRCCS, Rome, Italy and 4Department of Thoracic Medicine, Imperial College, School of Medicine at the National Heart and 
Lung Institute, London, UK
Email: Paolo Montuschi* - pmontuschi@rm.unicatt.it; Simona Martello - simona.martello@rm.unicatt.it; 
Marialinda Felli - marialinda.felli@rm.unicatt.it; Chiara Mondino - chwind@libero.it; Peter J Barnes - p.j.barnes@ic.ac.uk; 
Marcello Chiarotti - mchiarotti@rm.unicatt.it
* Corresponding author    
Abstract
Background: The role of leukotriene (LT) B4, a potent inflammatory mediator, in atopic asthmatic and atopic
nonasthmatic children is largely unknown. The lack of a gold standard technique for measuring LTB4 in exhaled
breath condensate (EBC) has hampered its quantitative assessment in this biological fluid. We sought to measure
LTB4 in EBC in atopic asthmatic children and atopic nonasthmatic children. Exhaled nitric oxide (NO) was
measured as an independent marker of airway inflammation.
Methods: Fifteen healthy children, 20 atopic nonasthmatic children, 25 steroid-naïve atopic asthmatic children,
and 22 atopic asthmatic children receiving inhaled corticosteroids were studied. The study design was of cross-
sectional type. Exhaled LTB4 concentrations were measured using liquid chromatography/mass spectrometry-
mass spectrometry (LC/MS/MS) with a triple quadrupole mass spectrometer. Exhaled NO was measured by
chemiluminescence with a single breath on-line method. LTB4 values were expressed as the total amount (in pg)
of eicosanoid expired in the 15-minute breath test. Kruskal-Wallis test was used to compare groups.
Results: Compared with healthy children [87.5 (82.5–102.5) pg, median and interquartile range], exhaled LTB4
was increased in steroid-naïve atopic asthmatic [255.1 (175.0–314.7) pg, p < 0.001], but not in atopic nonasthmatic
children [96.5 (87.3–102.5) pg, p = 0.59)]. Asthmatic children who were receiving inhaled corticosteroids had
lower concentrations of exhaled LTB4 than steroid-naïve asthmatics [125.0 (25.0–245.0) pg vs 255.1 (175.0–314.7)
pg, p < 0.01, respectively]. Exhaled NO was higher in atopic nonasthmatic children [16.2 (13.5–22.4) ppb, p <
0.05] and, to a greater extent, in atopic steroid-naïve asthmatic children [37.0 (31.7–57.6) ppb, p < 0.001] than in
healthy children [8.3 (6.1–9.9) ppb]. Compared with steroid-naïve asthmatic children, exhaled NO levels were
reduced in asthmatic children who were receiving inhaled corticosteroids [15.9 (11.5–31.7) ppb, p < 0.01].
Conclusion: In contrast to exhaled NO concentrations, exhaled LTB4 values are selectively elevated in steroid-
naïve atopic asthmatic children, but not in atopic nonasthmatic children. Although placebo control studies are
warranted, inhaled corticosteroids seem to reduce exhaled LTB4 in asthmatic children. LC/MS/MS analysis of
exhaled LTB4 might provide a non-invasive, sensitive, and quantitative method for airway inflammation assessment
in asthmatic children.
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Background
Chronic airway inflammation, the primary pathophysio-
logical feature of asthma, underlies asthma symptoms
and might have a role in airway and lung remodelling [1].
Elevated airway inflammation often precedes the onset of
symptoms or airway limitation [1]. Quantification of air-
way inflammation is difficult as it requires invasive tech-
niques or measurement of biomarkers in plasma or urine
which reflect systemic rather than lung inflammation.
Bronchoscopy with bronchoalveolar lavage remains the
gold standard to assess airway inflammation, but inva-
siveness makes it unethical as a routine method particu-
larly in children [2]. Sputum induction is less invasive [3],
although this technique is particularly difficult to apply in
young children and itself induces airway inflammation
[4].
This has led to a search for non-invasive ways to measure
airway and lung inflammation in order to aid diagnosis,
to assess response to anti-inflammatory treatments, to
predict loss of disease control and to assess the response
to novel treatments [5]. There is increasing evidence that
measurement of biomarkers in the breath may reflect pul-
monary disease [6]. Direct sampling form the lung has
major advantages compared with sampling form the
blood or urine, when dilution and metabolism of inflam-
matory markers arising in the lungs makes interpretation
very difficult. Exhaled nitric oxide (NO) measurement is
currently the only completely noninvasive method for
quantifying airway inflammation in patients with asthma
who are not treated with corticosteroids [2,7]. However,
as several inflammatory mediators are involved in
asthma, identification of other exhaled markers might
contribute to a better understanding of its complex patho-
physiology. Exhaled breath condensate (EBC) is a com-
pletely noninvasive method for collecting airway
secretions [8,9]. Cysteynyl-leukotrienes play an important
role in the pathophysiology of asthma and their regula-
tion is relevant for the management of this disease [10].
However, the role of leukotriene (LT) B4, a potent chem-
oattractant for neutrophils, in asthma is largely unknown.
Using immunoassays, LTB4 has been detected in EBC in
healthy subjects and found increased in asthmatic adults
[11,12] and children [13,14]. However, the presence of
LTB4 in EBC has not been confirmed by more specific ana-
lytical techniques. Moreover, a large variation in exhaled
LTB4 concentrations in patients with similar clinical and
functional features has been reported in different studies
[13-15]. This may be partially explained by the lack of val-
idation of commercially available immunoassay kits
which were used to measure exhaled LTB4 in these studies
[16]. Mass spectrometry, the reference analytical tech-
nique, is required for an accurate quantitative assessment
of exhaled LTB4. In the present study, we aimed to meas-
ure LTB4 concentrations in EBC with liquid chromatogra-
phy/mass spectrometry-mass spectrometry (LC/MS/MS)
using deuterated (d4) LTB4 as internal standard in healthy
children, atopic nonasthmatic children, steroid-naïve
atopic asthmatic children, and atopic asthmatic children
who were treated with inhaled corticosteroids. We also
measured exhaled NO as an independent marker of air-
way inflammation.
Methods
Study subjects
Four groups of children were studied: 15 healthy children,
20 atopic nonasthmatic children, 25 steroid-naïve atopic
asthmatic children, and 22 atopic asthmatic children who
were receiving inhaled corticosteroids (Table 1). Atopic
nonasthmatic and atopic asthmatic children were
recruited from the Asthma and Allergy outpatient clinic,
Istituto Dermopatico dell'Immacolata, Rome, Italy. The
diagnosis and classification of asthma was based on clini-
cal history and examination and pulmonary function
parameters according to the Guidelines for the Diagnosis
and Management of Asthma issued by the National Heart,
Lung, and Blood Institute of the National Institutes of
Health [17]. Steroid-naïve atopic asthmatic children had
mild intermittent asthma with symptoms less often than
twice a week, forced expiratory volume in one second
(FEV1) of 80% or greater of predicted value and reversibil-
ity of 12% or greater to salbutamol, or positive provoca-
tion test result with methacholine or exercise. They were
not taking any regular medication but used inhaled short-
acting  β2-agonists as needed for symptom relief. They
were excluded from the study if they had used inhaled cor-
ticosteroids or LT receptor antagonists in the previous 4
weeks. Atopy was confirmed by skin prick testing. Steroid-
treated atopic asthmatic children had persistent mild-to-
moderate asthma and were receiving maintenance ther-
apy with either 100 µg/day (10 children) or 200 µg/day
(12 children) of inhaled fluticasone propionate adminis-
tered by means of diskus (GSK, Uxbridge, United King-
dom) at a constant dose for at least 8 weeks. They had not
been taking LT receptor antagonists for at least one
month. Atopy was confirmed by skin prick tests.
Atopic nonasthmatic children had a clinical history of
atopy and positive skin test results. All had allergic rhinitis
and were either sensitized to perennial allergens or were
recently exposed to a relevant allergen.
Healthy control children had no history of asthma and
atopic disease and negative skin prick test results. They
were recruited from children of staff.
Study group children had no upper respiratory tract infec-
tions in the previous 3 weeks. Children were excluded
from the study if they had used oral corticosteroids in theRespiratory Research 2005, 6:119 http://respiratory-research.com/content/6/1/119
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previous 4 weeks or non-steroidal anti-inflammatory
drugs in the last 2 weeks.
Study design
The study was of cross-sectional design. Children attended
the Department of Pharmacology, Catholic University of
the Sacred Heart, Rome, Italy, for clinical examination,
EBC collection, spirometry and skin prick testing.
Informed consent was obtained by parents and the study
was approved by the Ethics Committee of the Catholic
University of the Sacred Heart, Rome, Italy.
Day-to-day repeatability for LTB4  measurements was
assessed in 20 children with asthma in a randomized
design by collecting three EBC samples within 7 days of
the first.
Pulmonary function
Spirometry was performed by means of a 10 L bell
spirometer (Biomedin, Padova, Italy) and the best of three
maneuvers, expressed as a percentage of predicted values,
was chosen.
Exhaled breath condensate collection
Exhaled breath condensate was collected using a condens-
ing chamber (Ecoscreen, Jaeger, Hoechberg, Germany) as
described previously [11]. Briefly, exhaled air entered and
left the chamber through one-way valves at the inlet and
outlet, thus keeping the chamber closed. Children were
instructed to breath tidally through a mouthpiece con-
nected to the condenser for 15 min. An average of 1.5 ml
EBC per child was collected and stored a -80°C. LTB4
measurements were performed within 2 weeks from sam-
ple collection. α-Amylase concentrations in all EBC sam-
ples were measured by an in vitro colorimetric method to
check for possible salivary contamination (Roche Diag-
nostics, Basel, Switzerland).
Measurement of exhaled LTB4
Exhaled LTB4 was measured with a Finnigan Surveyor®LC
System pump coupled with a TSQ Quantum Ultra™ triple
quadrupole mass spectrometer using electrospray ioniza-
tion with negative ion polarity mode with electrospray
source (Thermo Electron Corporation, San José, USA).
The LC/MS/MS experimental conditions were similar to
those described previously [18]. However, the use of a
Finnigan Surveyor®LC System pump coupled with a TSQ
Quantum Ultra™ triple quadrupole mass spectrometer
made it possible to increase 10 fold the analytical sensitiv-
ity (10 pg/ml vs 100 pg/ml). The lower limit of quantifi-
cation (LOQ) was 50 pg/ml. The optimized source
parameters were as follows: spray voltage, 4500 V; sheath
gas pressure, 40 arbitrary units; aux gas pressure, 10 arbi-
trary units; capillary temperature, 300°C; capillary offset,
30 V; tube lens offset, 110 V. Chromatography was per-
formed on a BetaBasic C18 column (15 cm × 2, 1 mm
internal diameter, Thermo Hypersil-Keyston, Bellefonte,
PA, USA) using a linear gradient with acetonitrile-water-
acetic acid (30:70:0.05, v/v, at pH 5–6) which was
changed to 100% acetonitrile over 4 minutes. Flow rate
was 0.25 ml/min. LTB4-d4 (Cayman Chemicals Co., Ann
Arbor, MI) was used as internal standard and was added
to each sample to reach a final concentration of 1000 pg/
ml. The peak area ratios for LTB4/LTB4-d4 were plotted ver-
sus LTB4 concentrations. The calibration curve in the range
10–500 pg/ml had a good linearity with r2 = 0.9965. 10 µl
of sample were directly injected into the liquid chromato-
graph without any pretreatment.
All solvents were high performance liquid chromatogra-
phy grade obtained from Merck (Darmstadt, Germany);
acetic acid extra pure was purchased by Riedel-de Haen,
Sigma-Aldrich, Seelze, Germany. LTB4 and LTB4-d4 were
purchased from Cayman Chemicals Co (Ann Arbor, MI,
USA) and stored at -20°C until use. The working solutions
were prepared daily using mobile phase as solvent.
Table 1: Subject characteristics§
Healthy children Atopic nonasthmatic 
children
Steroid-naïve atopic 
asthmatic children
Steroid-treated atopic 
asthmatic children
n 1 52 02 52 2
Sex, F/M 8/7 9/11 12/13 10/12
Age, yr 10 ± 1 9 ± 1 10 ± 1 10 ± 1
FEV1, % pred 101.5 ± 1.8 100.8 ± 2.3 96.1 ± 1.4 97.5 ± 2.3
FVC, % pred 102.7 ± 2.8 103.2 ± 2.5 100.4 ± 2.3 101.5 ± 2.7
FEV1/FVC, % 99.8 ± 1.5 97.5 ± 2.6 87.1 ± 2.3* 85.8 ± 2.5*
FEF25–75% 104.0 ± 3.8 101.8 ± 4.1 68.2 ± 3.9** 83.7 ± 4.5*
§ Data are expressed as numbers or mean ± SEM.
* P < 0.05 and ** P < 0.01 compared with healthy children. Steroid-treated asthmatic children were receiving either 100 µg/day or 200 µg/day of 
inhaled fluticasone at a constant dose for at least 8 weeks.Respiratory Research 2005, 6:119 http://respiratory-research.com/content/6/1/119
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LTB4 values in EBC were expressed as total amount (in
picograms) of leukotriene expired in the 15-minute
breath test (LT concentrations × volume of EBC). Concen-
tration of LTB4 in undetectable samples was considered 25
pg/ml corresponding to 50% of the lower limit of quanti-
fication (50 pg/ml).
Exhaled nitric oxide measurement
Exhaled NO was measured with the NIOX system (Aero-
crine, Stockholm, Sweden) with a single breath on-line
method according to American Thoracic Society guide-
lines [7]. Children inhaled NO-free air and exhaled
through a dynamic flow restrictor. Children were asked to
exhale to residual volume, insert the mouthpiece, inhale
to total lung capacity through a NO filter, and then to
exhale into the device through the same mouthpiece for
10 seconds at constant flow of 50 ml/sec with the aid of a
visual feedback on a computer screen. A negative pressure
tracing on the screen was used to confirm that children
were inhaling NO-free air. Exhalations were repeated after
1-minute relaxation period until the performance of three
exhaled NO values varied less than 10%. Exhaled NO
measurements were obtained before spirometry.
Statistical analysis
Linear regression analysis was used to assess the relation-
ship between LC peak area ratios for LTB4/LTB4-d4 and
LTB4 concentrations. Exhaled LTB4 and NO values were
expressed as medians throughout with interquartile
ranges (25th to 75th percentiles) shown in parentheses.
Kruskal-Wallis test followed by pairwise Mann-Whitney U
tests were used to compare groups. Correlations between
variables were evaluated by Spearman test. Significance
was defined as a value of p < 0.05.
Results
No α-amylase concentrations (<22 mU/ml) were detected
in any study sample, excluding significant salivary
contamination.
LTB4 in EBC
The mass spectra of LTB4 and LTB4-d4 revealed a base peak
at m/z 335 for endogenous LTB4 and m/z 339 for internal
standard LTB4-d4, corresponding to molecular ions. To
increase specificity, LTB4 was detected in MS/MS mode.
Parent ions m/z 335 and m/z 339 were fragmented with a
collision energy of 17% and 19%, respectively. The transi-
tion 335 → 195 m/z and 339 → 197 m/z for internal stand-
ard was monitored (Figure 1). Exhaled LTB4
concentrations were detected in all steroid-naïve atopic
asthmatics, atopic nonasthmatics, and healthy children
and were undetectable in 7 steroid-treated atopic asth-
matic children (Figure 2). Compared with healthy chil-
dren [87.5 (82.5–102.5) pg], exhaled LTB4 was increased
in steroid-naïve atopic asthmatic children [255.1 (175.0–
314.7) pg, p < 0.001], but not in atopic nonasthmatic chil-
dren [96.5 (87.3–102.5) pg, p = 0.59) (Figure 2). Steroid-
naïve children with atopic asthma had higher exhaled
LTB4 concentrations than atopic nonasthmatic children (p
< 0.001) and healthy children (p < 0.001) (Figure 2).
Asthmatic children who were receiving inhaled corticos-
teroids had lower concentrations of exhaled LTB4 than
steroid-naïve asthmatics [125.0 (25.0–245.0) pg vs 255.1
(175.0–314.7) pg, p < 0.01, respectively] and similar to
those in atopic nonasthmatic children (p = 0.41) and
healthy controls (p = 0.43) (Figure 2). In steroid-treated
atopic asthmatic children, subgroup analysis shows that
children who were receiving 100 µg/day of inhaled fluti-
casone at a constant dose for at least 8 weeks had higher
exhaled LTB4 values than those who were receiving with
200 µg/day of inhaled fluticasone at a constant dose for at
least 8 weeks [245.0 (235.0–282.5) pg vs 25.0 (25.0–
102.5) pg, p < 0.002, respectively) (Figure 3). In children
receiving 200 µg/day of fluticasone, median exhaled LTB4
values were similar to those in atopic nonasthmatic chil-
dren (p = 0.15) and healthy controls (p = 0.10). In con-
trast, exhaled LTB4 was elevated in asthmatic children who
were receiving 100 µg/day of inhaled fluticasone (atopic
nonasthmatic children: p < 0.005; healthy children: p <
0.001).
Seven asthmatic children who were treated with the
higher dose of fluticasone had undetectable levels of
exhaled LTB4 (Figure 3). MS/MS spectra of steroid-naïve
asthmatic children (Figure 1A), healthy children (Figure
1C), and atopic nonasthmatic children (not shown)
showed a major unknown peak in all samples. This peak
is not always present in steroid-treated asthmatic children
(not shown) and deserves further characterization. There
was no correlation between exhaled LTB4 and exhaled NO
in any study group. There was no correlation between
exhaled LTB4 or exhaled NO and age, sex, or lung function
in any study group. The intraclass correlation coefficient
for LTB4 was 0.89.
Exhaled NO
Exhaled NO was higher in atopic nonasthmatic children
[16.2 (13.5–22.4) ppb, p < 0.05] and, to a greater extent,
in steroid-naïve atopic asthmatic children [37.0 (31.7–
57.6) ppb, p < 0.001] than in healthy children [8.3 (6.1–
9.9) ppb] (Figure 4). Compared with steroid-naïve asth-
matic children, exhaled NO levels were reduced in asth-
matic children who were receiving inhaled corticosteroids
[15.9 (11.5–31.7) ppb, p < 0.01] (Figure 4). In these chil-
dren, exhaled NO concentrations were higher than those
in healthy controls (p < 0.01), but not than those in atopic
nonasthmatic children (p = 0.98) (Figure 4). There was no
difference in exhaled NO levels between asthmatic chil-
dren receiving 200 µg/day of inhaled fluticasone andRespiratory Research 2005, 6:119 http://respiratory-research.com/content/6/1/119
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children receiving a daily dose of 100 µg [14.1 (11.3–
22.9) ppb vs 19.8 (13.5–44.5) ppb, p = 0.27, respec-
tively)] (Figure 5). Both subgroups of steroid-treated asth-
matic children had higher exhaled NO levels than healthy
children (children treated with fluticasone at a dose of
100 µg/day: p < 0.001; children treated with fluticasone at
a dose of 200 µg/day: p < 0.001) but not than atopic non-
asthmatic children (children treated with fluticasone at
dose of 100 µg/day: p = 0.42; children treated with fluti-
casone at a dose of 200 µg/day: p = 0.46).
Discussion
EBC is a completely non-invasive method for sampling
secretions from the airways which is suitable for repeated
measures of lung inflammation even in young children
[19]. Using LTB4-d4 as internal standard, we have defini-
tively demonstrated that LTB4 is present in the EBC, pro-
viding an accurate quantitative assessment of its
concentrations in this biological fluid. In our study,
absolute LTB4 values in EBC are significantly higher than
those previously reported in studies using enzyme immu-
noassays [14,15], but similar to those found in studies in
which exhaled LTB4 was measured by MS analysis [18,20].
The reasons for this discrepancy are unknown but could
be partially related to matrix effects as differences in pro-
tein composition of the immunoassay buffer used for
LTB4 standard dilution versus EBC samples might influ-
ence LTB4  measurement. We avoided possible matrix
Liquid chromatography/mass spectrometry-mass spectrometry chromatograms of exhaled breath condensate (EBC) Figure 1
Liquid chromatography/mass spectrometry-mass spectrometry chromatograms of exhaled breath condensate 
(EBC). Samples from an asthmatic child (A and B) and a healthy child (C and D) are shown. The ions m/z 195 (A and C) and 
m/z 197 (B and D) were used to monitor endogenous leukotriene (LT) B4 and LTB4-d4 (internal standard), respectively. LTB4 
concentrations in EBC, calculated using peak area ratios for LTB4/LTB4-d4, were 87 pg/15 min (healthy child) and 450 pg/15 min 
(asthmatic child).
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effects as EBC samples were directly injected into the chro-
matograph without any pre-treatment. Our study popula-
tion of atopic asthmatic children had well maintained
lung function as indicated by FEV1 values greater than
80% of predicted values, but evidence for small airway
obstruction given that values of FEV1/FVC ratio and FEF25–
75%, which are more sensitive for detecting reduced lung
function in children [1], were decreased. Compared with
healthy control children, exhaled LTB4  concentrations
were selectively elevated in steroid-naïve children with
atopic asthma, but not in atopic nonasthmatic children
and in steroid-treated atopic asthmatic children.
Enhanced airway inflammation in steroid-naïve children
with asthma was confirmed by elevated exhaled NO levels
in these children. These findings indicate that exhaled
LTB4 can be used as a new in vivo non-invasive marker of
inflammation in steroid-naïve asthmatic children.
We did not study the effects of allergen challenge on
exhaled LTB4 in atopic nonasthmatic children and atopic
asthmatic children. Similar exhaled LTB4 values in healthy
children and atopic nonasthmatic children who had
either perennial rhinitis or were recently exposed to a rel-
evant allergen indicate that allergen exposure has little, if
any, effect on exhaled LTB4 in atopic nonasthmatic chil-
dren. However, allergen challenge studies to formally
address this issue are warranted. The effect of allergen
challenge on exhaled LTB4 levels in atopic asthmatic chil-
dren is unknown and needs to be clarified.
In contrast to exhaled LTB4, exhaled NO levels were ele-
vated in atopic nonasthmatic children although this
increase was less pronounced than in steroid-naïve atopic
asthmatic children. These findings and the lack of
correlation between exhaled LTB4 and exhaled NO levels
suggest a different biological significance for these two
biomarkers as exhaled LTB4 might be considered as a
marker of asthma, whereas exhaled NO might reflect the
different degree of inflammation within the respiratory
tract in atopic children with and without asthma. This
may have important implications for diagnosis and treat-
ment of children with allergic disease.
Measurement of exhaled LTB4 might help identify those
children with no current respiratory symptoms, well-
maintained lung function and elevated exhaled NO who
are not only atopic but have ongoing asthmatic inflam-
mation which may require earlier pharmacological ther-
apy. Moreover, elevated exhaled NO levels in atopic
nonasthmatic children with rhinitis reflect the presence of
inflammation within the airways as the restricted exhala-
tion method ensures velum closure excluding contamina-
tion of the exhaled air with nasal NO [7]. This is
consistent with a common origin for allergic rhinitis and
asthma [1]. However, larger studies are needed to assess
Leukotriene (LT) B4 concentrations in exhaled breath con- densate in children with allergic disease Figure 2
Leukotriene (LT) B4 concentrations in exhaled 
breath condensate in children with allergic disease. 
Exhaled LTB4 concentrations in healthy children (open 
squares), atopic non-asthmatic children (NA) (filled squares), 
steroid-naïve atopic asthmatic children (open triangles), and 
steroid-treated (ST) children with atopic asthma (filled trian-
gles). LTB4 values are expressed as picograms produced dur-
ing 15 minutes of breathing. Median values are shown with 
horizontal bars.
Leukotriene (LT) B4 concentrations in exhaled breath con- densate in steroid-treated children with atopic asthma Figure 3
Leukotriene (LT) B4 concentrations in exhaled 
breath condensate in steroid-treated children with 
atopic asthma. Exhaled LTB4 concentrations in atopic asth-
matic children who were receiving either 100 µg/day (open 
squares) or 200 µg/day (filled squares) of inhaled fluticasone 
at a constant dose for at least 8 weeks. LTB4 values are 
expressed as picograms produced during 15 minutes of 
breathing. Median values are shown with horizontal bars.
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the biological significance of these findings and their
implications.
In the present study, median exhaled LTB4 concentrations
in children who were receiving inhaled fluticasone were
lower than those in steroid-naïve asthmatic children. A
significant reduction in exhaled LTB4 levels was observed
only in the group of children who were receiving 200 µg/
day of inhaled fluticasone, whereas in children who were
receiving a daily dose of inhaled fluticasone of 100 µg
median exhaled LTB4 levels were similar to those in ster-
oid-naïve asthmatic children. These findings might indi-
cate that the lower dose of fluticasone is unable to reduce
exhaled LTB4 levels in asthmatic children. However, there
was a high individual variability in exhaled LTB4 concen-
trations in both subgroups of steroid-treated asthmatic
children as well as in steroid-naïve asthmatic children
which needs to be addressed in future studies. In a previ-
ous open-label uncontrolled study, treatment with
inhaled fluticasone (100 µg twice a day for 4 weeks) had
no effect on exhaled LTB4 concentrations in atopic asth-
matic children with similar features [14]. This might be
due to differences in the study design (open-label vs
observational), duration of treatment (4 weeks vs at least
8 weeks), and the analytical technique used for measuring
LTB4 in EBC (enzyme immunoassay vs LC/MS/MS) as
concentrations of exhaled LTB4 measured by MS are 10-
fold higher than those measured by immunoassay. How-
ever, the cross-sectional study design of the present study
precludes definitive conclusions on the effect of inhaled
corticosteroids on exhaled LTB4 in asthmatic children for
which large controlled studies are required.
One limitation of the EBC analysis is that the cellular
source of the inflammatory mediators within the airways
cannot be ascertained. To this aim, invasive techniques
such as bronchial biopsies are required.
To adjust for possible variations in the EBC sample vol-
ume, LTB4 values in EBC were expressed as total amount
of the eicosanoid expired over a standard period of collec-
tion. However, as pointed out by Effros and coworkers,
part of the variation in non-volatile compound concentra-
tions in EBC may be related to differences in the dilution
of respiratory droplets by water vapor [21]. The lack of
correlation between structurally related compounds such
as LTB4 and LTE4 reported in previous studies [13,14] does
not seem to support this evidence. However, reference
indicators such as measurement of conductivity as
proposed by Effros and coworkers [22] should be used in
future studies aiming at quantifying exhaled eicosanoids.
Conclusion
Exhaled LTB4 is elevated in steroid-naïve atopic asthmatic
children, but not in children receiving inhaled
Exhaled nitric oxide (NO) concentrations in children with  allergic disease Figure 4
Exhaled nitric oxide (NO) concentrations in children 
with allergic disease. Exhaled NO concentrations in 
healthy children (open squares), atopic non-asthmatic chil-
dren (NA) (filled squares), steroid-naïve atopic asthmatic 
children (open triangles), and steroid-treated (ST) children 
with atopic asthma (filled triangles). Median values are shown 
with horizontal bars.
Exhaled nitric oxide (NO) concentrations in exhaled breath  condensate in steroid-treated children with atopic asthma Figure 5
Exhaled nitric oxide (NO) concentrations in exhaled 
breath condensate in steroid-treated children with 
atopic asthma. Exhaled NO concentrations in atopic asth-
matic children who were receiving either 100 µg/day (open 
squares) or 200 µg/day (filled squares) of inhaled fluticasone 
at a constant dose for at least 8 weeks. Median values are 
shown with horizontal bars.
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corticosteroids and in atopic nonasthmatic children. LC/
MS/MS analysis of exhaled LTB4 might provide a com-
pletely non-invasive, sensitive, and quantitative method
for airway inflammation assessment in asthmatic chil-
dren. This technique is potentially applicable to patients
with other lung diseases and suitable for longitudinal
studies and assessing pharmacological therapy. The high
cost is currently an important limitation. Further research
is warranted for the complete characterization of the
exhaled substances including cysteinyl-leukotrienes and
for establishing the effect anti-asthmatic drugs on exhaled
LTB4.
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